Search clinical trials for: 89Zr-bevacizumab

Total 2561 results

Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
GlaxoSmithKline

Completed

Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors

Neoplasms | Cancer

Netherlands
BioNTech Research & Development, Inc.
SciQuus Oncology

Terminated

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Pancreatic Carcinoma | Tumors That Express CA19-9

United States
University Medical Center Groningen

Withdrawn

89Zr-RO5323441 PET Imaging in Glioblastoma

Glioblastoma

Netherlands
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
University Medical Center Groningen

Terminated

89Zr-atezolizumab PET Scan and Lobular Breast Cancer (ImaGelato)

Lobular Metastatic Breast Cancer

Netherlands
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University

Completed

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Glioblastoma

United States
VU University of Amsterdam

Completed

SLN in Colon Cancer Using a Multimodal Tracer

Sentinel Lymph Node

Netherlands
Telix Pharmaceuticals (Innovations) Pty Limited
Merck KGaA, Darmstadt, Germany

Recruiting

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Advanced Solid Tumor | Solid Tumor, Adult | Advanced Renal Cell Carcinoma

Australia
Crescendo Biologics Ltd.
University Medical Center Groningen

Active, not recruiting

A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions

Advanced and/or Metastatic Solid Tumours

Netherlands
Memorial Sloan Kettering Cancer Center

Withdrawn

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Multiple Myeloma
ImaginAb, Inc.
University of Hull

Recruiting

CD8 Minibody Repeatability Study (PRETZCEL)

Melanoma | Renal Cell Carcinoma

United Kingdom
Aplagon Oy
TRACER Europe BV

Recruiting

Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) (CHASE)

Peripheral Arterial Occlusive Disease | Critical Limb Ischemia

Netherlands
University of Alabama at Birmingham

Withdrawn

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer (Panitumumab)

Metastatic Colon Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Pituitary Adenoma | Brain Cancer

United States
Washington University School of Medicine
Molecular Templates, Inc.

Withdrawn

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

HER2-positive Solid Tumor | HER-2 Positive Cancer
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC

Unknown

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Non Small Cell Lung Cancer

Netherlands
University Medical Center Groningen

Completed

Clinical Value of 89Zr-trastuzumab PET

Metastatic Breast Cancer

Netherlands
Stanford University

Withdrawn

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Pancreas Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Multiple Myeloma

United States
University of Alabama at Birmingham

Recruiting

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
Amsterdam UMC, location VUmc
Foundation for the National Institutes of Health

Not yet recruiting

Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer (iRelate)

NSCLC

Netherlands
Andrei Iagaru

Not yet recruiting

Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Head-and-neck Squamous Cell Carcinoma

United States
Boehringer Ingelheim

Terminated

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung

Netherlands
Qingdao Central Hospital

Recruiting

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Hoag Memorial Hospital Presbyterian

Recruiting

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

Multiple Myeloma

United States
Nerissa T. Viola

Not yet recruiting

First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

Non Small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Lymphoma | Metastatic Malignant Solid Neoplasm

United States
Amsterdam UMC, location VUmc
AstraZeneca

Recruiting

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study (HER Image)

Breast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Cancer

Netherlands
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Netherlands
Memorial Sloan Kettering Cancer Center

Completed

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Esophagogastric Cancer

United States
University Medical Center Groningen
Regeneron Pharmaceuticals

Active, not recruiting

LAG3 PET Imaging in Advanced Solid Tumors

Metastatic Solid Tumor

Netherlands
The Netherlands Cancer Institute
Daiichi Sankyo, Inc.

Not yet recruiting

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

EGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
University of Alabama at Birmingham

Recruiting

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; Broad Institute

Completed

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Early Cancer Detection in People at High Risk of Developing Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cyst

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Renal Impairment | Healthy Volunteer

United States, Czechia, Hungary, Poland
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain Neoplasm

United States, Canada
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditions

United States, Canada
Memorial Sloan Kettering Cancer Center

Recruiting

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

Small Cell Lung Carcinoma | Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States
Northwestern University
National Cancer Institute (NCI); Ipsen Biopharmaceuticals

Completed

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Metastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma

United States
Karolinska University Hospital

Recruiting

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer (MIMIR-mTNBC)

Metastatic Triple-Negative Breast Carcinoma

Sweden
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

Breast Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States

Search clinical trials for: 89Zr-bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations